Fax: (713) 745-1462
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer
Version of Record online: 5 MAY 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 14, pages 3330–3337, 15 July 2010
How to Cite
Krishnamurthy, S., Cristofanilli, M., Singh, B., Reuben, J., Gao, H., Cohen, E. N., Andreopoulou, E., Hall, C. S., Lodhi, A., Jackson, S. and Lucci, A. (2010), Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer, 116: 3330–3337. doi: 10.1002/cncr.25145
- Issue online: 2 JUL 2010
- Version of Record online: 5 MAY 2010
- Manuscript Accepted: 2 NOV 2009
- Manuscript Revised: 28 OCT 2009
- Manuscript Received: 26 JUN 2009
- Department of Defense Breast Cancer Research Program. Grant Number: Award DAMD 17-03-01-0669
- Society of Surgical Oncology Clinical Investigator Award, and The M. D. Anderson Institute for Personalized Cancer Therapy
- State of Texas Rare and Aggressive Breast Cancer Research program
- Morgan Welch Inflammatory Breast Cancer Research program and clinic
- circulating tumor cells;
- disseminated tumor cells;
- breast cancer;
- prognostic markers;
- bone marrow aspiration
The significance of circulating tumor cells (CTCs) in blood and of disseminated tumor cells (DTCs) in bone marrow (BM) in patients with early stage breast cancer is unclear. In this study, the authors investigated the occurrence of CTCs and DTCs in women with early stage breast cancer and evaluated the correlation of their presence with other prognostic markers.
Blood and BM aspirations were collected at the time of primary breast surgery. CTCs were detected by using the CellSearch assay, and DTCs were detected by immunostaining BM aspirates for pancytokeratin. The presence of CTCs and DTCs was correlated with tumor classification (T1 vs T2), tumor histologic grade, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, and lymph node (LN) status.
Of 92 patients who were included in the study, 49 had T1 tumors, and 43 had T2 tumors. CTCs were detected in 31% of patients, and DTCs were detected in 27% of patients. There was no correlation between the occurrence of CTCs and DTCs with the tumor classification (T1 vs T2) or histologic grade. CTCs were detected in 33% of patients with ER-positive disease versus 26% of patients with ER-negative disease, in 32% of patients with PR-positive disease versus 30% of patients with PR-negative disease, and in 25% of patients with HER2-positive disease versus 31% of patients with HER2-negative disease. DTCs were observed in 23% of patients with ER-positive disease versus 37% of patients with ER-negative disease, in 22% of patients with PR-positive disease versus 32% of patients with PR-negative disease, and in 0% of patients with HER2-positive disease versus 29% of patients with HER2-negative disease. CTCs and DTCs were nearly equally prevalent in both LN-positive women and LN-negative women. There was no significant correlation between the occurrence of CTCs or DTCs with tumor classification (T1 vs T2), tumor histologic grade, positive ER status, positive PR status, or positive HER2 status, and axillary LN status.
CTCs and DTCs in women with early stage breast cancer did not correlate with the standard prognostic indicators that were considered. The implications of their occurrence in patients with early stage disease will require further large-scale studies. Cancer 2010. © 2010 American Cancer Society.